Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rabepirin
- Development stage
- Unknown
- Lead developer
- Dongkwang Chemical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rabepirin (DKP103) is an oral fixed-dose combination (FDC) therapy developed by Dongkwang, consisting of the antiplatelet agent aspirin and the proton pump inhibitor (PPI) rabeprazole. Classified as an 'improved new drug' (incrementally modified drug) in South Korea, it is indicated for the prevention of cardiovascular events in patients who require long-term aspirin therapy but are at high risk for developing gastric or duodenal ulcers. Aspirin provides antithrombotic effects by irreversibly inhibiting cyclooxygenase-1 (COX-1), which prevents the synthesis of thromboxane A2 and subsequent platelet aggregation. Rabeprazole mitigates the gastrointestinal side effects of aspirin by irreversibly inhibiting the H+/K+-ATPase enzyme system (the proton pump) in gastric parietal cells, thereby reducing gastric acid secretion. Rabepirin was approved and launched in South Korea in 2024.
- Brand names
- RabepirinRabepirin Capsule
- Other names
- 라베피린캡슐
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on Rabepirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rabepirin.